WuXi PharmaTech Begins Operation of New High-Potency API Laboratory

SHANGHAI, May 28, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. WX, a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today announced that its manufacturing subsidiary, Syn-The-All Pharmaceutical Co., Ltd. (STA), has begun operation of a high-potency active pharmaceutical ingredient (HPAPI) laboratory in Shanghai, thereby adding HPAPI processing to its portfolio of services. The lab will support process development and clinical-trial supply of high-potency small molecules at kilogram scale.

"With the increasing use of HPAPIs in drug discovery and development, this new service augments WuXi's ability to provide highly efficient and cost-effective solutions for our partners worldwide," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech.

Technical inquiries regarding process development and clinical-trial supply of high-potency API materials can be made by contacting STAinfo@wuxiapptec.com .

About WuXi PharmaTech

WuXi PharmaTech WX is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States.  As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process.  WuXi PharmaTech's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D.  The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec.

For more information, please contact:

Ronald Aldridge
Director of Investor Relations
+1 (201) 585-2048
ron_aldridge@wuxiapptec.com  

Aaron Shi
Associate Director of Corporate Communications
+86-21-5046-4362
aaron_shi@wuxiapptec.com

SOURCE WuXi PharmaTech (Cayman) Inc.